J&J secures FDA OK for immune drug touted as future blockbuster
The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
The company has predicted that Imaavy — now approved for generalized myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.
